Biomaterials for Reproductive Restoration: Translating Engineering Innovations
Abstract
Advances in cancer therapy, delayed parenthood, and an increasing number of reproductive disorders have intensified the need for the effective preservation of fertility. However, current clinical strategies such as ovarian tissue cryopreservation, transplantation, and hormonal stimulation remain limited in scope and efficacy. Biomaterials have emerged as powerful tools to overcome these limitations, enabling fertility preservation and functional restoration of reproductive and endocrine systems. Recent progress has included the development of hydrogel-based systems for in vitro follicle maturation, bioengineered scaffolds for ovarian tissue support, and artificial ovaries capable of hormone secretion and oocyte development. These platforms are increasingly incorporating immunomodulatory features to address rejection and enhance graft integration. Beyond preservation, biomaterials are also being harnessed to repair reproductive damage caused by conditions such as primary ovarian insufficiency, intrauterine adhesions, and endometriosis. Through tunable biochemical and mechanical properties, materials can direct tissue regeneration, modulate inflammation, and restore physiological functions. Emerging technologies, including biofabrication with reproductive-specific bioinks, organoid models, hormone-responsive systems, and artificial intelligence-driven biomaterial designs, are accelerating innovation toward translational applications. Collectively, these developments represent…
How strong is the evidence?
Evidence Hub reads this as a review, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.